SCHEMBL5887360

SCHEMBL5887360

C=CCNc1nc(C)c2ccc(=O)n(-c3ccc(C(=O)NCC4CCCCC4)cc3)c2n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.41
MLYCD O95822 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
CA2 P00918 1/20 0.38
POLB P06746 2/20 0.37
NAMPT P43490 5/20 0.37
LMNA P02545 2/20 0.36
HPGD P15428 2/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
THRB P10828 1/20 0.35
CNR1 P21554 2/20 0.35
MAPK14 Q16539 1/20 0.35
CNR2 P34972 1/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886743 0.88 MMP13 (0.42) MMP13MLYCDHDAC6CA2POLB
SCHEMBL5887431 0.87 MMP13 (0.41) MMP13MLYCDHDAC6CA2POLB
SCHEMBL5886916 0.87 HPGD (0.54) POLBLMNAHPGDMAPTRAB9A
SCHEMBL5886835 0.87 MMP13 (0.43) MMP13MLYCDHDAC6CA2POLB
SCHEMBL5887055 0.87 ALDH1A1 (0.43) MMP13MLYCDHDAC6CA2POLB
SCHEMBL5887385 0.87 MAPT (0.41) MMP13MLYCDHDAC6CA2POLB
SCHEMBL5887046 0.86 MMP13 (0.39) MMP13MLYCDHDAC6CA2POLB
SCHEMBL5887490 0.85 MAPK8 (0.40) LMNAMAPTRAB9ASMN1; SMN2THRB
SCHEMBL5886937 0.85 ALDH1A1 (0.44) MMP13POLBHPGDMAPTSMN1; SMN2
SCHEMBL5886984 0.84 RAB9A (0.36) MLYCDNAMPTLMNAHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP MMP13 3469/4885MLYCD 3072/4885HDAC6 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.